Truist Financial Corp Sells 20,634 Shares of Danaher Corporation (NYSE:DHR)

Truist Financial Corp decreased its stake in Danaher Corporation (NYSE:DHR - Free Report) by 5.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 359,487 shares of the conglomerate's stock after selling 20,634 shares during the period. Truist Financial Corp owned approximately 0.05% of Danaher worth $73,695,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in DHR. Fortis Capital Advisors LLC grew its holdings in shares of Danaher by 1.3% during the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after buying an additional 50 shares in the last quarter. Fayez Sarofim & Co grew its holdings in shares of Danaher by 0.6% during the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after buying an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC grew its holdings in shares of Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after buying an additional 50 shares in the last quarter. Perennial Investment Advisors LLC grew its holdings in shares of Danaher by 2.2% during the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock worth $538,000 after buying an additional 51 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC grew its holdings in Danaher by 3.1% in the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock valued at $399,000 after purchasing an additional 52 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.

Insider Buying and Selling at Danaher

In related news, EVP Christopher Paul Riley sold 15,805 shares of the stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president owned 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the sale, the chairman owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their position. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by corporate insiders.

Danaher Price Performance

Shares of NYSE:DHR traded up $1.07 during trading on Tuesday, reaching $200.70. The company had a trading volume of 4,225,555 shares, compared to its average volume of 3,502,202. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $281.70. The firm has a market capitalization of $143.63 billion, a PE ratio of 38.97, a price-to-earnings-growth ratio of 2.80 and a beta of 0.77. The firm's fifty day moving average is $195.71 and its 200 day moving average is $206.90. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. On average, equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.64%. Danaher's dividend payout ratio is currently 24.85%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent research reports. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. UBS Group dropped their price target on shares of Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Evercore ISI lowered their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research note on Tuesday. Royal Bank Of Canada reiterated an "outperform" rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. Finally, Bank of America lowered their target price on shares of Danaher from $265.00 to $230.00 in a research note on Monday, April 14th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $248.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.